The CDMO Capacity Crunch With Discovery Labs' Audrey Greenberg and Iovance Biotherapeutics' Sumit Verma
Business Of Biotech
00:00
CDMO - What Are the Risks?
The biggest risk always is going to be partnering with the wrong strategic CDMO player for your overall efforts. The intrinsic values of patient care you know do they share the same passion and energy around curative medicine that plays a big role. Choosing the wrong CDMO can have truly detrimental effects in all these areas especially when you think about the small biotech and some gene therapy companies who already come in with limited time limited resources.
Transcript
Play full episode
